Epicrispr builds case for epigenetic muscle disease treatment with updated data

Epicrispr reports updated trial data for epigenetic editing treatment in FSHD muscular dystrophy

Epicrispr Biotechnologies presented encouraging updated findings from testing of its epigenetic editing treatment for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disease. The data builds the case for the company's therapeutic approach to treating the condition.